Underserved communities with diabetes also have higher HbA1cs, diabetes distress, and mortality rates and lower utilization of new therapeutic approaches and technologies including insulin pumps and continuous glucose monitoring (CGM) systems, which can improve glycemic outcomes [18–21]. This evidence concerns the gene INS and diabetes mellitus.